PHT 427

Key Product Details

Product Description

PHT 427 is a dual Akt and PDK1 inhibitor; binds the pleckstrin homology (PH) domain of Akt and PDK1 (K_i values are 2.7 and 5.2 μM, respectively). Inhibits Akt phosphorylation and Akt downstream targets; also induces apoptosis in vitro. Displays synergistic antitumor effect when combined with chemotherapeutics in breast cancer mouse models.

Product Specifications for PHT 427

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for PHT 427

The following data is based on the product molecular weight 409.61.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.44 mL	12.21 mL	24.41 mL
5 mM	0.49 mL	2.44 mL	4.88 mL
10 mM	0.24 mL	1.22 mL	2.44 mL
50 mM	0.05 mL	0.24 mL	0.49 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Meuillet Molecular pharmacology and antitumor activity of PHT-427, a novel Akt/phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitor. Mol.Cancer Ther. 2010 PMID: 20197390
• Moses In vitro and in vivo activity of novel small-molecule inhibitors targeting the pleckstrin homology domain of protein kinase B/AKT. Cancer Res. 2009 PMID: 19491272

Product Documents for PHT 427